Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobic, Emir, Gill, Christian M, Mochon, A Brian, Nicolasora, Nelson P, Nicolau, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Novel ID Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266675/
https://www.ncbi.nlm.nih.gov/pubmed/34250190
http://dx.doi.org/10.1093/ofid/ofab252
_version_ 1783719989532950528
author Kobic, Emir
Gill, Christian M
Mochon, A Brian
Nicolasora, Nelson P
Nicolau, David P
author_facet Kobic, Emir
Gill, Christian M
Mochon, A Brian
Nicolasora, Nelson P
Nicolau, David P
author_sort Kobic, Emir
collection PubMed
description Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described.
format Online
Article
Text
id pubmed-8266675
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82666752021-07-09 Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration Kobic, Emir Gill, Christian M Mochon, A Brian Nicolasora, Nelson P Nicolau, David P Open Forum Infect Dis Novel ID Cases Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described. Oxford University Press 2021-05-25 /pmc/articles/PMC8266675/ /pubmed/34250190 http://dx.doi.org/10.1093/ofid/ofab252 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Novel ID Cases
Kobic, Emir
Gill, Christian M
Mochon, A Brian
Nicolasora, Nelson P
Nicolau, David P
Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title_full Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title_fullStr Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title_full_unstemmed Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title_short Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration
title_sort cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration
topic Novel ID Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266675/
https://www.ncbi.nlm.nih.gov/pubmed/34250190
http://dx.doi.org/10.1093/ofid/ofab252
work_keys_str_mv AT kobicemir cefiderocolpharmacokineticsinapatientreceivingcontinuousvenovenoushemodiafiltration
AT gillchristianm cefiderocolpharmacokineticsinapatientreceivingcontinuousvenovenoushemodiafiltration
AT mochonabrian cefiderocolpharmacokineticsinapatientreceivingcontinuousvenovenoushemodiafiltration
AT nicolasoranelsonp cefiderocolpharmacokineticsinapatientreceivingcontinuousvenovenoushemodiafiltration
AT nicolaudavidp cefiderocolpharmacokineticsinapatientreceivingcontinuousvenovenoushemodiafiltration

Ejemplares similares